Rigel Pharmaceuticals, Inc. (RIGL) Hit a 52 Week High, Can the Run Continue?

Core Insights - Rigel Pharmaceuticals (RIGL) shares have increased by 73.3% over the past month and 203% since the beginning of the year, outperforming the Zacks Medical sector and the Zacks Medical - Drugs industry [1] - The company has consistently beaten earnings estimates, reporting an EPS of $1.46 against a consensus estimate of $0.93 in its last earnings report [2] - For the current fiscal year, Rigel is projected to achieve earnings of $6.54 per share on revenues of $290.75 million, reflecting a 560.61% increase in EPS and a 62.18% increase in revenues [3] Valuation Metrics - Rigel has a Value Score of B, with Growth and Momentum Scores both rated A, resulting in a combined VGM Score of A [6] - The stock trades at 7.8X current fiscal year EPS estimates, significantly lower than the peer industry average of 20.7X, while on a trailing cash flow basis, it trades at 47.2X compared to the peer group's average of 15.5X [6] Zacks Rank - Rigel holds a Zacks Rank of 2 (Buy), supported by favorable earnings estimate revisions from analysts, indicating potential for further gains [7] Competitive Landscape - Aurinia Pharmaceuticals Inc (AUPH), a peer in the industry, also shows strong performance with a Zacks Rank of 2 (Buy) and has gained 34% over the past month [8][10] - AUPH is expected to post earnings of $0.85 per share on revenues of $280.35 million for the current fiscal year, having beaten consensus estimates by 43.75% last quarter [9]